LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...
(RTTNews) - Drug major Merck & Co., Inc. (MRK) Friday announced positive results of Phase 3 trials with its anti-PD-1 therapy KEYTRUDA (pembrolizumab) in various cancers. In the Phase 3 KEYNOTE-756 ...
“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.
The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey (Reuters) - Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with ...
Clinical Trials Arena on MSN
Padcev-Keytruda notches another phase III win in bladder cancer
Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s cisplatin eligibility.
Merck & Co Inc (NYSE:MRK) and Eisai Co Ltd (OTC:ESALY) (OTC: ESALF) have provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating Keytuda plus Lenvima, in patients with certain types ...
Thursday, Merck & Co Inc (NYSE:MRK) released topline data from the Phase 3 KEYLYNK-006 trial evaluating Keytruda (pembrolizumab) in combination with maintenance Lynparza (olaparib) for certain ...
Merck & Co. said it has stopped enrollment in two Phase III trials assessing its cancer immunotherapy Keytruda ® (pembrolizumab) in combination with other therapies to treat multiple myeloma, ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA in combination with ...
Merck’s Keytruda is riding a winning streak in bladder cancer. Following FDA approvals in the metastatic and non-muscle invasive settings, the anti-PD-1 therapy has delivered a positive readout in ...
A clinical trial has started to evaluate the investigational drug MK-1084 and Keytruda among some patients with metastatic non-small cell lung cancer. A phase 3 clinical trial has been launched among ...
CHICAGO, June 3 (Reuters) - New trial results show that Merck & Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback